The Care Stack

Tariffs and drug shortages are a data problem now

Victor Wilson · · 3 min read

Pharmacy and supply chain leaders have always dealt with price changes and shortages. This year, both got harder at the same time.

Most of the response is clinical and operational. Pharmacists pick substitutes. Buyers find other sources. But a lot of it depends on data the health system already has and often can’t pull together fast. That part belongs to the data team.

What changed this year

Tariffs came to drugs. In April, the President signed a Section 232 proclamation putting tariffs of up to 100% on imported brand drugs and their ingredients. Generics and biosimilars are excluded for now. Companies with approved US manufacturing plans pay 20%. The tariffs started July 31 for 17 large drugmakers and Sept. 29 for everyone else.

Shortages are climbing again. ASHP counted 227 active drug shortages in the second quarter, the third quarterly increase in a row. That’s below the record of 323 in early 2024, but the trend is going the wrong way.

Costs are already up. Kaufman Hall’s October report found drug expense per adjusted discharge up 6% this year and supplies up 5%. And Vizient projects hospital pharmacy prices will rise another 3.54% in 2027. That figure leaves tariffs out.

Why this lands on the data team

Each of these changes raises a question that only data can answer quickly.

Which of our drugs are exposed? A tariff on imported brand drugs matters a lot for some health systems and very little for others. It depends on what you buy and from whom. Answering that means joining purchase history to product details like manufacturer and whether the item is brand or generic. Ask your team how long that would take. If the answer is weeks, that’s your first project.

What do we use when something runs short? When a drug goes on the shortage list, pharmacy needs to know right away how much you use and what you have on hand. Then it needs to track the substitutes it chose, so it can see whether usage shifted and whether costs jumped. The answers often sit in separate systems.

Are we still paying what we agreed to pay? When costs rise upstream, prices on invoices tend to move too. Some of that is allowed under your contracts. Some of it isn’t. Price drift was already a quiet leak before this year. With drug costs up 6%, each missed difference costs more.

There’s one more thing to watch. HRSA published a revised 340B rebate pilot in August, with a target start of Jan. 1, 2027. If it goes ahead, some discounts you now get up front could arrive later as rebates. Money that arrives later has to be tracked, or it tends not to arrive at all.

What to build, and where agents help

You don’t need a new system. You need three views that pharmacy and supply chain trust.

An exposure list. Every drug and major supply item you buy, with yearly spend, manufacturer, and whether it’s brand or generic. Sort by spend. The top of that list is where tariffs and price increases will hurt most.

A shortage watch. Match the current shortage list to your own usage every week. For each drug that’s short and that you use, show your days of supply and which units use it most. Note any substitutes pharmacy has approved before.

A price check. Compare invoice prices to contract prices on your top items every month. Flag differences and send them to a named buyer.

AI agents can do much of the legwork here. An agent can check new shortage notices against your formulary each morning and draft a short note for the pharmacy team. It can read invoices, match them to contract terms, and flag lines that don’t agree. It can pull usage history when a buyer needs it for a call with a supplier.

People still make the calls that matter. Pharmacists and your pharmacy and therapeutics committee decide which substitutes are safe. Buyers decide which price differences to dispute. The agent gets them the facts faster. It doesn’t decide what a patient receives.

Here’s the ask. Before the end of the year, ask your pharmacy and supply chain leaders whether they could answer two questions within a day. Which of our top 50 drugs by spend are imported brand products? And which drugs on the current shortage list do we use most? If either answer would take weeks, build that view first.

Discussion

    Join the discussion